Telix Pharmaceuticals (TLX) Receivables Refunds (2023 - 2025)

Telix Pharmaceuticals (TLX) has disclosed Receivables Refunds for 3 consecutive years, with $6.0 million as the latest value for Q4 2025.

  • Quarterly Receivables Refunds fell 2.87% to $6.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.0 million through Dec 2025, down 2.87% year-over-year, with the annual reading at $6.0 million for FY2025, 2.22% up from the prior year.
  • Receivables Refunds for Q4 2025 was $6.0 million at Telix Pharmaceuticals, down from $6.2 million in the prior quarter.
  • The five-year high for Receivables Refunds was $6.2 million in Q4 2024, with the low at $3.1 million in Q4 2023.
  • Average Receivables Refunds over 3 years is $5.1 million, with a median of $6.0 million recorded in 2025.
  • The sharpest move saw Receivables Refunds soared 101.67% in 2024, then decreased 2.87% in 2025.
  • Over 3 years, Receivables Refunds stood at $3.1 million in 2023, then skyrocketed by 101.67% to $6.2 million in 2024, then dropped by 2.87% to $6.0 million in 2025.
  • According to Business Quant data, Receivables Refunds over the past three periods came in at $6.0 million, $6.2 million, and $3.1 million for Q4 2025, Q4 2024, and Q4 2023 respectively.